2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. Calcium Channel

Calcium Channel

Ca2+ channels; Ca channels

Calcium Channel

Related Products

PDF 4.86 MB

Calcium channel is an ion channel which displays selective permeability to calcium ions. It is sometimes synonymous as voltage-dependent calcium channel, although there are also ligand-gated calcium channels. Voltage-gated calcium (CaV) channels catalyse rapid, highly selective influx of Ca2+ into cells despite a 70-fold higher extracellular concentration of Na+. Some calcium channel blockers have the added benefit of slowing your heart rate, which can further reduce blood pressure, relieve chest pain (angina) and control an irregular heartbeat.

Calcium Channel Isoform Specific Products:

Calcium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-103059
    SOICR-IN-1
    		99.62%
    SOICR-IN-1 (compound 32) is a store-overload induced calcium release (SOICR) inhibitor with an IC50 value of 14.6 μM. SOICR-IN-1 can be used for the research of cardiac arrhythmias.
    SOICR-IN-1
  • HY-113308S1
    Taurolithocholic acid-d4
    		Agonist 98.36%
    Taurolithocholic acid-d4 is deuterium labeled Taurolithocholic acid.
    Taurolithocholic acid-d<sub>4</sub>
  • HY-N2005
    Cycleanine
    		Inhibitor 99.80%
    Cycleanine is a potent vascular selective Calcium antagonist. Cycleanine has analgesic, muscle relaxant and anti-inflammatory activities. Cycleanine has potential for anti-ovarian cancer acting through the apoptosis pathway.
    Cycleanine
  • HY-110292
    A-425619
    		Inhibitor 99.96%
    A-425619 is an orally active and selective transient receptor potential type V1 (TRPV1) antagonist. A-425619 blocks Capsaicin (HY-10448)- and N-arachidonoyl-dopamine (NADA)-induced Ca2+ influx in dorsal root ganglia and trigeminal ganglia. A-425619 relieves pathophysiological pain associated with inflammation and tissue injury in rats. A-425619 can be used for the study of pain related to inflammation and tissue injury.
    A-425619
  • HY-N0126R
    Xanthone (Standard)
    		Inhibitor
    Xanthone (Standard) is the analytical standard of Xanthone (HY-N0126). This product is intended for research and analytical applications. Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K+-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca2+ channels. Xanthone is the scaffold of several pharmacologically active compounds.
    Xanthone (Standard)
  • HY-106454
    N-Desalkylflurazepam
    		Inhibitor 99.95%
    N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively.
    N-Desalkylflurazepam
  • HY-105084A
    Lubeluzole dihydrochloride
    		Inhibitor 99.00%
    Lubeluzole dihydrochloride is the dihydrochloride salt of Lubeluzole (HY-105084). Lubeluzole is the S-isomer of benzothiazole derivative. Lubeluzole can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole exhibits anti-ischemic and neuroprotective effects. Lubeluzole also shows anti-bacterial and anti-diarrheal potential. Lubeluzole can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian.
    Lubeluzole dihydrochloride
  • HY-N4267
    Yangambin
    		Inhibitor 98.27%
    Yangambin, a furofuran lignan, is already isolated from plants such as member of the Annonaceae family, including species of the genus Rollinia: R. pickeli, R. exalbidaand R. mucosa, as well from the Magnolia biondii. Yangambin, a selective PAF receptor antagonist, inhibits Ca2+ influx through voltage-gated Ca2+ channels, leading to the reduction in [Ca2+]i in vascular smooth muscle cells and consequent peripheral vasodilation. Yangambin exhibits the antiallergic activity against β-hexosaminidase release with an IC50 of 33.8 μM and for anti-inflammatory activity with an IC50 of 37.4 μM.
    Yangambin
  • HY-U00044
    Anipamil
    		Antagonist 99.34%
    Anipamil is a long-acting calcium channel blocker, used for the treatment of cardiovascular disease.
    Anipamil
  • HY-B0166S3
    L-Ascorbic acid-13C-2
    L-Ascorbic acid-13C-2 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen
    L-Ascorbic acid-<sup>13</sup>C-2
  • HY-B0424S
    Nitrendipine-d5
    		Inhibitor 99.76%
    Nitrendipine-d5 is the deuterium labeled Nitrendipine (HY-B0424). Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma.
    Nitrendipine-d<sub>5</sub>
  • HY-110255A
    AZD 2066 hydrate
    		Inhibitor ≥99.0%
    AZD-2066 hydrate is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 hydrate activates the BDNF/trkB signaling pathway. AZD 2066 hydrate can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease.
    AZD 2066 hydrate
  • HY-132268
    Cav 2.2 blocker 2
    		Inhibitor 98.45%
    Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid.
    Cav 2.2 blocker 2
  • HY-111014
    VK-II-36
    		Activator 99.63%
    VK-II-36 is a carvedilol analog that suppresses sarcoplasmic reticulum Ca2+release but does not block the β-receptor.VK-II-36 inhibits triggered activities evoked by both early and delayed after depolarizations.
    VK-II-36
  • HY-P10358
    TAT-CBD3A6K
    		98.26%
    TAT-CBD3A6K, is a modified TAT-CBD3 peptide. TAT-CBD3A6K reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function.
    TAT-CBD3A6K
  • HY-P5114
    Maurocalcine
    		Agonist
    Maurocalcine is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocalcine induces [3H]ryanodine binding on RyR1 with an EC50 value of 2558 nM. Maurocalcine exhibits a apparent affinity of 14 nM for RyR2. Maurocalcine can be applied to in vivo cell tracking or other cell imaging techniques.
    Maurocalcine
  • HY-100119
    Enecadin
    		Inhibitor 99.71%
    Enecadin is a neuroprotective agent extracted from patent US 8623823 B2.
    Enecadin
  • HY-113037CS
    Farnesyl pyrophosphate-d2 triammonium
    		Agonist
    Farnesyl pyrophosphate-d2 (Farnesyl diphosphate-d2) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d<sub>2</sub> triammonium
  • HY-N1584AR
    Halofuginone hydrobromide (Standard)
    		Inhibitor
    Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
    Halofuginone hydrobromide (Standard)
  • HY-66010A
    Cinepazide
    		Inhibitor
    Cinepazide is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al.
    Cinepazide
Cat. No. Product Name / Synonyms Application Reactivity
Calcium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.